pre-IPO PHARMA

COMPANY OVERVIEW

EUSA Pharma is a global speciality pharmaceutical company, continuously striving to confront current gaps in patient care. Their ambition drives us to deliver medical treatments that deliver real change to improve patients lives wherever they are needed in the world.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://www.eusapharma.com/


CAREER WEBSITE

https://www.eusapharma.com/careers.html


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Dec 2, 2021

BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease


Aug 17, 2021

BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma


Aug 17, 2021

BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma


Mar 24, 2021

Medidata Acorn AI Supports EUSA Pharma’s Relaunch of SYLVANT in the US Market


Jan 25, 2021

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT (Siltuximab for Injection) in China


For More Press Releases


Google Analytics Alternative